ArticleJournal of education and health promotion2025
Grade II obesity is an independent predictor of poor response to ovulation induction with oral letrozole in infertile women with PCOS: A prospective cohort study from North India.
Article in Journal of education and health promotion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Function of anti-müllerian hormone (AMH), gonadotropins and FSHR rs6166 genetic variant in the pathogenesis and diagnostic assessment of polycystic ovary syndrome.Journal of education and health promotion · 2026Article
- Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists.Frontiers in nutrition · 2026Review
- Synergistic Impact of Obesity and PCOS on Immune Dysregulation: A Review of Systemic and Local Inflammatory Profiles.International journal of women's health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLetrozole is an effective ovulation-inducing agent for women with Polycystic Ovary Syndrome (PCOS), but its efficacy may be influenced by obesity. This study examines obesity's impact on letrozole-induced ovulation in infertile women with PCOS. MATERIAL AND
methodsA prospective cohort study was conducted at a tertiary medical center in North India with 80 anovulatory women with PCOS. Participants received letrozole (5 mg daily, days 2-6) for up to three cycles. Ovulation was monitored through transvaginal ultrasound, and human chorionic gonadotrophin (HCG) was administered when a dominant follicle reached ≥ 17 mm. The association between obesity and letrozole response was assessed, considering clinical, metabolic, and hormonal parameters. Categorical variables were analyzed using the Chi-square test, and continuous variables were compared via Student's
resultsEighty participants were recruited in the study including 51 (63.75%) responders and 29 (36.25%) nonresponders. Higher BMI, elevated AMH, and increased testosterone levels were linked to a negative response to letrozole. Grade II obesity (BMI ≥30 kg/m²) significantly reduced the likelihood of ovulation (adjusted OR 8.49, 95% CI 1.06-67.56,
conclusionsGrade II obesity is an independent risk factor for poor response to letrozole ovulation induction in PCOS. Personalized treatment based on BMI may enhance success rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.